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BACKGROUND: Post-molar pregnancy gestational trophoblastic tumours (GTT) have been curable with chemotherapy treatment for
over 50 years. Because of the rarity of the diagnosis, detailed structured information on prognosis, treatment escalations and outcome
is limited.
METHODS: We have reviewed the demographics, prognostic variables, treatment course and clinical outcomes for the post-mole GTT
patients treated at Charing Cross Hospital between 2000 and 2009.
RESULTS: Of the 618 women studied, 547 had a diagnosis of complete mole, 13 complete mole with a twin conception and 58 partial
moles. At the commencement of treatment, 94% of patients were in the FIGO low-risk group (score 0–6). For patients treated with
single-agent methotrexate, the primary cure rate ranged from 75% for a FIGO score of 0–1 through to 31% for those with a FIGO
score of 6.
CONCLUSION: In the setting of a formal follow-up programme, the expected cure rate for GTT after a molar pregnancy should be
100%. Prompt treatment and diagnosis should limit the exposure of most patients to combination chemotherapy. Because of the
post-treatment relapse rate of 3% post-chemotherapy, hCG monitoring should be performed routinely.
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Gestational trophoblastic tumours (GTT) form a family of rare
diagnoses, including molar pregnancies, invasive mole, choriocar-
cinoma and placental site tumours. These are each characterised as
arising from the cells of conception producing hCG and having
extremely high sensitivity to chemotherapy (Seckl et al, 2010).
Although these tumours are rare, they have been routinely curable
with treatment for over 50 years (Hertz et al, 1956). One of the
main considerations of current treatments is to maintain cure
rates, while minimising exposure to excess chemotherapy, in view
of the potential negative effects on fertility and future second
tumour risks (Rustin et al, 1996; Bower et al, 1998).
In the United Kingdom, all patients diagnosed with a molar
pregnancy are registered centrally for hCG monitoring and followed
up, with the patients requiring treatment receiving care in the two
units at Charing Cross Hospital in London and Weston Park
Hospital in Sheffield. This centralised approach to care has allowed
the development of considerable clinical experience and the
collection of accurate data on outcomes from large numbers of
patients (Bower et al, 1997; McNeish et al, 2002; El-Helw et al, 2009).
Despite the overall high cure rates in GTT, there remain some
areas of ongoing clinical debate. These include the optimum
schedule of methotrexate (MTX) administration, the comparative
benefits of single-agent therapy with MTX or dactinomycin for
low-risk patients and the appropriate point to locate the cut-off
values between low- and high (or intermediate)-risk patients, and
hence their initial treatments. However, the development of
routinely curative chemotherapy for GTT predates the introduc-
tion of randomised clinical trials in cancer treatment by a number
of decades, and as these rare illnesses have extremely high cure
rates with their established therapies, developing prospective trials
remains challenging (Alazzam et al, 2009; Lertkhachonsuk et al,
2009).
In this paper we present the demographics, disease stage,
prognostic scores and treatment outcomes for 618 women treated
for post-molar pregnancy GTT at Charing Cross Hospital in the
decade 2000–2009. The data in this series may be of value in
designing clinical trials, discussing individual risks and treatment
options with patients, and supporting the development of
centralised services in other countries.
PATIENTS AND METHODS
Patient database and selection
The electronic database of the Trophoblastic Disease Centre at
Charing Cross Hospital in London was reviewed for all cases of
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GTT following molar pregnancies treated between 2000 and 2009.
The patients included in this series all had a prior uterine
evacuation, confirmed molar histology, met the Charing Cross
Hospital guidelines for treatment and had a follow-up of at least 1
year after the completion of therapy.
The guideline indications for treatment after a molar pregnancy
include the following components: heavy PV bleeding, rising hCG
levels over a 2- to 4-week period, an hCG plateau of 4 weeks or
longer, or a serum hCG level 420 000 IU l 1 more than 4 weeks
after evacuation (Savage et al, 2008). Patients meeting these
criteria were then assessed according to the FIGO scoring system
as shown in Table 1, and grouped as either low risk (0 to 6) or high
risk (46; Ngan et al, 2003).
Pre-treatment assessment
All patients were assessed clinically with a Doppler ultrasound
scan of the pelvis, a chest X-ray (CXR) and an updated serum hCG
level. On the basis of this assessment, patients were given a
prognostic score according to the FIGO scoring system.
All patients with pulmonary metastases visible on the CXR went
on to have a CT scan of the chest, abdomen and pelvis, and a brain
MRI scan.
Treatment protocols
The standard first-line therapy for patients with a FIGO score of 6
or lower was the Charing Cross Hospital MTX and folinic acid (FA)
regimen. A small number of patients with adverse characteristics,
such as heavy bleeding, hCG levels over 250 000 IU l 1 or a con-
traindication to intramuscular administration were commenced on
first-line treatment with either D1-5 dactinomycin or the EMA–CO
combination regimen.
Patients with CXR-detected pulmonary metastases received CNS
prophylaxis with intrathecal MTX (12.5mg) every 2 weeks for
three doses, with treatment timed to coincide shortly after one of
the i.m. doses of MTX.
During treatment, patients had their serum hCG levels measured
twice weekly, and three static or two rising hCG values were
defined as drug-resistant disease and the patient was changed to a
more intensive therapy.
The next treatment regimen was determined by their current
hCG levels, with those with hCG levels o300 IU l 1 receiving
single-agent dactinomycin and those with hCG levels
of4300 IU l 1 commencing on EMA–CO. Patients developing
second-line resistance to dactinomycin were changed on EMA–CO
chemotherapy.
For the small number of post-molar pregnancy patients scoring
in the high-risk category (WHO score46), the first-line treatment
was the EMA–CO regimen. Any of these high-risk patients who
developed resistance or excessive toxicity were changed to the
taxol–etoposide/taxol–cisplatin (TE/TP) doublet regimen (Wang
et al, 2008).
In all cases, chemotherapy treatment was continued until
normalisation of serum hCG level (o5 IU l 1) and then for an
additional 6 weeks of consolidation therapy.
For a small number of patients with drug-resistant disease or
relapse localised to the uterus, a hysterectomy was performed.
After completing chemotherapy, lifelong hCG follow-up was
commenced and patients were defined as having had a relapse if, in
the absence of a new pregnancy, hCG levels start to rise after the
hCG level has been in the normal range for 6 weeks.
Treatment regimens
Methotrexate/folinic acid MTX 50mg i.m. days 1, 3, 5 and 7, and
FA tablet 15mg days 2, 4, 6 and 8, repeated every 14 days.
Dactinomycin Dactinomycin 0.5mg i.v. days 1–5, repeated every
14 days.
EMA–CO D1: etoposide 100mgm 2, dactinomycin 0.5mg, MTX
300mgm 2. D2: etoposide 100mgm 2, dactinomycin 0.5mg. D8:
cyclophosphamide 600mgm 2, vincristine 0.8mgm 2, repeated
every 14 days.
RESULTS
Patients treated and FIGO scores
Between 2000 and 2009, 9010 women with molar pregnancies were
registered for screening at the Charing Cross Hospital. During this
10-year-period, a total of 746 patients were treated at the Charing
Cross Hospital for GTT, following a molar pregnancy; and of these,
128 have been excluded from this study primarily because of
overseas residence, unverified histology or incomplete follow-up.
Of the remaining 618 post-mole GTT patients, 91% had a
diagnosis of a prior complete molar pregnancy and 9% developed
GTT following a partial molar pregnancy. The median age at the
start of treatment was 32 years, with an overall age range between
15 and 56 years. The results of the FIGO prognostic scoring are
shown in Table 2, with 579 (94%) of the 618 patients falling into
the low-risk (0–6 FIGO score) category and only 39 (6%) patients
of the study population falling into the high-risk group.
Treatment outcomes
Low-risk group The overall results of the low-risk treatment
group of patients are shown in Table 3. For the 579 FIGO low-risk
score patients, 554 patients received first-line treatment with MTX/
FA, with 316 patients successfully completing their therapy using
this regimen alone, producing an overall successful treatment rate
of 57%. For the 238 patients who started MTX/FA but required
more intensive treatment, the choice of second-line treatment was
dependent on the hCG level at the time of the introduction of the
Table 1 The FIGO Prognostic Scoring System for gestational trophoblast tumours
FIGO scoring 0 1 2 4
Age (years) o40 440 — —
Antecedent pregnancy Mole Abortion Term —
Interval months from end of index pregnancy to treatment o4 4p7 7p13 413
Pretreatment serum hCG (IU l 1) o103 103p104 104p105 4105
Largest tumour size, including uterus (cm) o3 3p5 45 —
Size of metastasis Lung Spleen, kidney Gastro-intestinal Liver, brain
Number of metastases — 1–4 5–8 48
Previous failed chemotherapy — — Single drug Two or more drugs
Abbreviation: FIGO¼ Fe´de´ration Internationale de Gyne´cologie et d’Obste´trique. Patient with a total score of 0–6 fall into the low-risk prognostic group, scores of 7 and over
are in the high-risk group.
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second-line treatment. For patients with an hCG level under
300 IU l 1 single-agent dactinomycin was the standard treatment,
whereas for women with an hCG level in excess of 300 IU l 1 at the
time of treatment escalation EMA–CO was the treatment choice. Of
the 96 patients treated with the second-line dactinomycin regimen
91 (95%), completed their treatment successfully without requiring
additional therapy. For the 142 MTX/FA patients receiving second-
line treatment with EMA–CO, only 2 required a further treatment
change in both cases to TE/TP because of excess EMA–CO toxicity.
Alongside the majority of FIGO low-risk patients starting
treatment with MTX/FA, three low-risk patients received single-
agent dactinomycin as their first-line treatment, with two of them
requiring additional EMA–CO second-line treatment. As a result of
either heavy bleeding, patient choice or concerns regarding the
role of MTX/FA in patients with very high hCG levels, 22 low-risk
patients were electively started on first-line therapy with EMA–CO,
and all were successfully treated with this as their first-line therapy
as reported in a previous publication (McGrath et al, 2010).
High-risk group High-risk disease with a FIGO score in excess of
6 is relatively rare in the post-mole GTT population, with only 39
(6%) patients in this group. Of these, three chose to have first-line
treatment with MTX/FA, which was unsuccessful in all. These
patients were then successfully cured with EMA–CO. From the
36 high-risk patients starting with first-line EMA–CO treatment,
33 were cured with this regimen, with the other 3 successfully
treated with a change to either cisplatin-based chemotherapy or
hysterectomy.
Response by FIGO prognostic score and disease sites The treat-
ment outcomes of all 618 patients were analysed according to their
FIGO prognostic scores as shown in Table 4. This demonstrates the
reducing efficacy of MTX/FA with the increasing prognostic score.
For patients with a FIGO score of 0 and 1, the primary success rate
is 75%, but falls to less than 50% for patients with FIGO scores of
3–5. For patients with a FIGO score of 6 treated with MTX/FA, the
primary success rate is 31%; however, it is apparent that only half
of this group started on MTX/FA with the others starting directly
with more intensive first-line therapies so potentially, positively
biasing this result.
The treatment results were also analysed according to the
documented sites of disease as shown in Table 5. This
demonstrates that from the total of 618 patients, 83 (13.5%) had
no visible tumour mass on their routine imaging and that the large
majority, 76%, had disease limited to the uterus. The spread of
disease beyond the pelvis was rare, occurring in just 10% of the
patients, with the lungs being the only documented site of disease.
The declining success rate with first-line MTX/FA with more
advanced stage matches closely with the results of the FIGO score,
ranging from 74% for those with no visible tumour to 55% for
patients with disease limited to the uterus, and falling to 36% for
patients with lung metastases visible on their CXR.
Relapses As shown in Table 6, there were 18 relapses from the
618 patients giving an overall risk of relapse of approximately 3%.
All the patients who relapsed had originally been within the
Table 2 The FIGO prognostic score analysis of the 618 women treated
for GTT following a molar pregnancy at the Charing Cross Hospital,
2000–2009
FIGO score Patient number (%) FIGO score Patient number (%)
0 53 (8.6) 7 20 (3.2)
1 90 (14.6) 8 12 (1.9)
2 122 (19.8) 9 4 (0.6)
3 138 (22.3) 10 3 (0.5)
4 96 (15.5) — —
5 49 (7.9) — —
6 31 (5.0) — —
Total low risk 579 (93.7) Total high risk 39 (6.3)
Abbreviations: FIGO¼ Fe´de´ration Internationale de Gyne´cologie et d’Obste´trique;
GTT¼ gestational trophoblastic tumour.
Table 3 The overall treatment results for the 618 women treated for
GTT after a molar pregnancy
Low-risk FIGO 0–6 Highrisk FIGO 7–10
Number Success
(%)
Number Success
(%)
First-line chemotherapy (579) First-line chemotherapy (39)
MTX/FA 554 57 MTX/FA 3 0
Dactinomycin 3 33 EMA–CO 36 92
EMA–CO 22 100 — — —
Second-line chemotherapy (238) Second-line chemotherapy (6)
Dactinomycin 96 94 EMA–CO 3 100
EMA–CO 142 99 TE/TP 3 33
Thirdline chemotherapy (7) Third-line treatment (2)
EMA–CO 5 100 Hysterectomy 2 100
TE/TP 2 100
Abbreviations: EMA–CO¼ etoposide, MTX, actinomycin D, cyclophosphamide,
vincristine; FA¼ folinic acid; FIGO¼ Fe´de´ration Internationale de Gyne´cologie et
d’Obste´trique; GTT¼ gestational trophoblastic tumour; MTX¼methotrexate;
TE¼ taxol–etoposide; TP¼ taxol–cisplatin. The table shows the outcomes separately
for the 579 women in the low-risk prognostic groups and 39 high-risk patients. All the
patients in both groups were cured.
Table 4 The successful treatment rates for single-agent MTX/FA chemotherapy and second-line therapies grouped by the patients FIGO prognostic score
FIGO
score
First-line
MTX/FA
Success rate
(%)
Second-line
dactinomycin
Success rate
(%)
Second-line
EMA–CO
Success rate
(%)
Third-line
EMA–CO
Success rate
(%)
0 53 77 12 92 — — 1 100
1 89 74 15 100 8 100 — —
2 122 67 14 86 26 100 2 100
3 138 47 28 93 45 100 2 100
4 93 45 21 100 30 100 — —
5 43 35 5 100 23 100 — —
6 16 31 1 100 10 90 — —
7 3 0 0 — 3 100 — —
Total 557
Abbreviations: EMA–CO¼ etoposide, MTX, actinomycin D, cyclophosphamide, vincristine; FA¼ folinic acid; FIGO¼ Fe´de´ration Internationale de Gyne´cologie et d’Obste´trique;
MTX¼methotrexate.
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FIGO 0–5 score groups. Treatment had been with MTX/FA alone in
nine of them and combined with either dactinomycin or EMA–CO
for the others.
On relapse, 13 of the patients received EMA-CO treatment to
achieve cure, 4 had chemotherapy with the TE/TP regimen and 2
patients underwent a hysterectomy. All of the relapse patients were
successfully salvaged and cured.
DISCUSSION
Gestational trophoblast tumours occurring after a molar preg-
nancy have been routinely curable with chemotherapy for over 50
years (Hertz et al, 1956). However, these tumours are rare in any
individual hospital and their effective treatment considerably
predates the modern era of randomised clinical trials. As a result,
the current standard treatment protocols are based on empirical
observations but are supported by a number of larger treatment
series, such as this and others, published both by our group and
other GTT units (McNeish et al, 2002; El-Helw et al, 2009; Fulop
et al, 2010).
Overall post-mole GTT is an illness in which the expectation
from treatment is one of cure; the data in this study demonstrates
in Table 3 that all 618 patients were successfully treated. The
majority of patients only required treatment with low-toxicity
single-agent chemotherapy, whereas 34% of patients required
combination chemotherapy, and only 2 patients required a
hysterectomy. This data is similar to our previous cohort and for
other treatment series, both from the GTT service in Sheffield (El-
Helw et al, 2009), and other centres in Europe (Chalouhi et al,
2009; Fulop et al, 2010), Asia (Kang et al, 2010) and North America
(Hoekstra et al, 2008; Growdon et al, 2010).
The standard assessment of GTT patients includes the FIGO
prognostic score, which is based on a number of key clinical
parameters and allows an estimate of the likely first-line cure rate
with the low-intensity single-agent drug treatment. During the
study period, 94% of the post-molar pregnancy GTT patients fell
into the FIGO low-risk grouping. The value of the prognostic
scoring is reflected in a falling success rate of first-line therapy
with a rising FIGO score. For FIGO scores 0 and 1, the rate is 75%
but falls to just under 50% for groups 3–5, whereas for patients in
the prognostic score 6 group the success rate for MTX/FA was
31%. However, almost 50% of this prognostic score group were
electively treated with more intensive chemotherapy from the
outset, as they were judged unlikely to respond satisfactorily to
MTX/FA. As a result, it is likely that true overall success rate for
MTX/FA in FIGO score 6 patients could be considerably lower.
The management of patients with prognostic scores of 4–6 has
been an area of debate, with some groups treating these patients
as an ‘intermediate-risk group’ and receiving first-line treatment
with dactinomycin (McNeish et al, 2002). Currently, the debate
regarding the more formal introduction of the intermediate
grouping is ongoing (Aghajanian, 2011) and a multicentre trial
examining the comparative benefits of MTX and actinomycin is
opening shortly. The data in this paper may help reflect what the
results of the current MTX/FA-based treatment delivers and
support the discussion on the subject.
Although the FIGO scoring system is now the most widely used
approach to determine prognosis and first-line treatment intensity,
historically a number of patients are treated following assessment
on conventional staging (Homesley, 1994). The results in Table 5
demonstrate the disease locations for the 618 patients treated and
their treatment outcome with first-line MTX/FA treatment. Of the
group, only 10% had spread outside of the pelvis, with lung
metastases visible on their CXRs. Of note, during routine staging
and more extensive CT staging in selected patients, no cases of
spread to any other sites were documented in any of these post-
mole GTT patients.
The first-line treatment outcome shows that the anatomical
staging results parallel the FIGO system, with more advanced
disease being less likely to be cured with single-agent MTX/FA.
The MTX/FA success rates were 74% for those with serological
disease only, 55% for those with disease limited to the uterus and
only 36% for those with lung metastases.
For patients who were started on MTX/FA, but developed evidence
of MTX resistance, we have historically used an hCG cut-off value of
100 IU l 1 to determine with single-agent dactinomycin or a
combination EMA–CO is used as the second-line treatment. In this
recent study, we have used a higher cut-off value of 300 IU l 1, which
has produced an overall second-line dactinomycin success rate of 94%
that compares favourably with the 87% reported when the cut-off value
was 100 IU l 1. With this update, we are confident that dactinomycin
can be safely used in these patients with a high chance of cure and
much lower toxicity than would occur with the EMA–CO treatment.
Following successful therapy relapse of post-mole GTT is rare,
with the data in Table 6 showing an overall relapse rate of 3.3%.
The relapses were fairly evenly distributed among patients treated
with MTX/FA and those receiving more complex therapies.
Fortunately, all the relapse patients were cured with additional
salvage chemotherapy or surgery. The low rate of relapse and high
subsequent cure rate supports a policy of informing treated
patients that they are almost certainly cured (97%), but that they
should take part in a structured hCG follow-up programme
because of the small (3%) chance of relapse.
Overall, the data in this series confirms that the previously
reported uniform cure rates for patients with post-molar
pregnancy GTT supports the grading of treatment intensity using
the FIGO scoring system, and may be of value to others treating
GTT in designing clinical trials, developing centralised treatment
centres or updating therapeutic guidelines.
Table 5 The breakdown of the disease clinical stage and successful
treatment rate for MTX/FA for the 618 post-molar pregnancy GTT
patients
Disease site
Patients
(%)
Median
hCG
(IU l 1)
First-line
treatment with
MTX/FA
First-line
MTX/FA success
rate (%)
hCG only 58 (9) 302 58 74
Uterine
vascularity
with no mass
25 (4) 2388 25 56
Uterine mass 467 (76) 16 571 430 57
Uterus and
adnexae
7 (1) 27 019 5 40
Uterus and
lungs
61 (10) 24 117 39 36
Total 618 557
Abbreviations: FA¼ folinic acid; GTT¼ gestational trophoblastic tumour;
GTT¼ gestational trophoblastic tumour; hCG¼ human chorionic gonadotropin;
MTX¼methotrexate.
Table 6 The relapse rates for patients after apparently successful initial
treatment for post-molar pregnancy GTT
Treatment group Relapse Total %
All low-risk patients 18 579 3.1
MTX/FA 9 313 2.9
MTX and actino 6 99 6.1
MTX and EMA–CO 3 143 2.8
Abbreviations: EMA–CO¼ etoposide, MTX, actinomycin D, cyclophosphamide,
vincristine; FA¼ folinic acid; GTT¼ gestational trophoblastic tumour;
MTX¼methotrexate.
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